One of India's leading pharmaceutical companies, Piramal Life Sciences has announced that it has started the phase-II study into its upcoming diabetic drug.
The company's Managing Director Somesh Sharma revealed that the phase-II study of 'P1736-05' has been started and the company was confident of a successful completion of the study.
The P1736-05 is an insulin sensitizing compound which will be a part of the company's new drug for the treatment of type-2 diabetes in India and Europe.
"The commencement of phase-II trial of P1736-05 in India and Europe speaks of our efforts to build a diversified and strong pipeline of products to address unmet medical needs. P1736-05 is likely to provide a safe and effective therapeutic option to type-2 diabetic patients", Sharma added.